Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes

Atopic dermatitis (AD) significantly impacts physical, social, and psychological well-being. Recently, novel, more effective treatment options have been approved, including those targeting interleukin-13. Watch this webcast for expert insights on incorporating these agents to optimize care for patients with moderate to severe AD.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education (PACE)

Supporters

This activity is supported by an educational grant from Lilly.

Lilly